Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Mar 29, 2023

SELL
$16.14 - $23.55 $260,273 - $379,767
-16,126 Reduced 54.67%
13,370 $310,000
Q3 2022

Nov 14, 2022

BUY
$15.46 - $20.1 $456,008 - $592,869
29,496 New
29,496 $473,000
Q1 2022

May 16, 2022

SELL
$17.2 - $22.5 $310,700 - $406,440
-18,064 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$17.5 - $21.35 $316,120 - $385,666
18,064 New
18,064 $537,000
Q2 2021

Aug 16, 2021

SELL
$21.74 - $25.28 $293,903 - $341,760
-13,519 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$19.25 - $26.1 $170,285 - $230,880
-8,846 Reduced 39.55%
13,519 $320,000
Q4 2020

Feb 16, 2021

BUY
$17.83 - $22.29 $398,767 - $498,515
22,365 New
22,365 $448,000
Q3 2020

Nov 13, 2020

SELL
$15.78 - $20.82 $814,784 - $1.08 Million
-51,634 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$15.49 - $23.51 $66,064 - $100,270
-4,265 Reduced 7.63%
51,634 $904,000
Q1 2020

May 15, 2020

BUY
$13.89 - $25.45 $776,437 - $1.42 Million
55,899 New
55,899 $913,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.12B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.